More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival showing for its combo could prohibit a broader FDA approval in ovarian cancer. More: ESMO: AstraZeneca faces challenge
read moreMerck offered a closer look at Keytruda’s overall survival benefits in a PD-L1-positive subgroup and its broader progression-free survival win at ESMO 2025. More: ESMO: Merck spotlights details of Keytruda's landmark win in ovarian cancer Source: fierce
read moreThe FDA has endorsed Amgen and AstraZeneca’s Tezspire as an add-on maintenance treatment for patients age 12 and older with chronic rhinosinusitis with nasal polyps. It is the second indication for Tezspire, which was originally approved in 2021 for severe
read moreAstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early breast cancer in two pivotal clinical trials. More: ESMO: AZ, Daiichi unleash Enhertu's 2-fisted power, aiming to reshape early breast cancer
read moreFertility drugmaker EMD Serono, the U.S. arm of Merck KGaA, will offer its in vitro fertilization (IVF) treatments at a sharp discount on the government’s DTC platform TrumpRx. More: Merck KGaA’s EMD Serono strikes MFN deal in Trump's fertility treatment
read moreEurope’s Committee for Medicinal Products for Human Use (CHMP) has given a thumbs down to Sanofi’s Rezurock as a third-line treatment for chronic graft-versus-host disease (cGVHD). The treatment has been on the market in the U.S. for four years. More:
read more© 1994 - 2026 B.M. Pharmaceuticals